IDEXX Laboratories Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 6/6
IDEXX Laboratories verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 14.9%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 8.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 10.5%. Die Eigenkapitalrendite von IDEXX Laboratories beträgt 55.2% und die Nettomargen betragen 23.3%.
Wichtige Informationen
14.9%
Wachstumsrate der Gewinne
15.8%
EPS-Wachstumsrate
Medical Equipment Wachstum der Industrie | 8.9% |
Wachstumsrate der Einnahmen | 10.5% |
Eigenkapitalrendite | 55.2% |
Netto-Marge | 23.3% |
Nächste Ertragsaktualisierung | 06 Aug 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?
Apr 23With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting
Apr 09Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Mar 07IDEXX Laboratories And Its Real Value
Feb 02Aufschlüsselung der Einnahmen und Ausgaben
Wie IDEXX Laboratories Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
31 Mar 24 | 3,725 | 867 | 925 | 199 |
31 Dec 23 | 3,661 | 845 | 902 | 191 |
30 Sep 23 | 3,588 | 823 | 888 | 183 |
30 Jun 23 | 3,514 | 791 | 877 | 183 |
31 Mar 23 | 3,431 | 699 | 858 | 259 |
31 Dec 22 | 3,367 | 679 | 851 | 255 |
30 Sep 22 | 3,340 | 670 | 848 | 257 |
30 Jun 22 | 3,309 | 664 | 840 | 249 |
31 Mar 22 | 3,274 | 735 | 821 | 164 |
31 Dec 21 | 3,215 | 745 | 796 | 161 |
30 Sep 21 | 3,135 | 757 | 770 | 154 |
30 Jun 21 | 3,047 | 728 | 777 | 152 |
31 Mar 21 | 2,858 | 674 | 739 | 146 |
31 Dec 20 | 2,707 | 582 | 735 | 141 |
30 Sep 20 | 2,591 | 497 | 717 | 138 |
30 Jun 20 | 2,475 | 460 | 674 | 134 |
31 Mar 20 | 2,457 | 437 | 681 | 135 |
31 Dec 19 | 2,407 | 428 | 669 | 133 |
30 Sep 19 | 2,351 | 423 | 657 | 128 |
30 Jun 19 | 2,291 | 407 | 642 | 123 |
31 Mar 19 | 2,252 | 390 | 638 | 120 |
31 Dec 18 | 2,213 | 377 | 632 | 118 |
30 Sep 18 | 2,170 | 330 | 621 | 117 |
30 Jun 18 | 2,117 | 307 | 610 | 115 |
31 Mar 18 | 2,045 | 284 | 596 | 112 |
31 Dec 17 | 1,969 | 263 | 575 | 109 |
30 Sep 17 | 1,906 | 277 | 561 | 106 |
30 Jun 17 | 1,862 | 263 | 547 | 104 |
31 Mar 17 | 1,820 | 245 | 534 | 102 |
31 Dec 16 | 1,775 | 222 | 522 | 101 |
30 Sep 16 | 1,732 | 214 | 516 | 101 |
30 Jun 16 | 1,690 | 202 | 502 | 100 |
31 Mar 16 | 1,637 | 192 | 493 | 99 |
31 Dec 15 | 1,602 | 192 | 482 | 100 |
30 Sep 15 | 1,554 | 174 | 475 | 99 |
30 Jun 15 | 1,531 | 182 | 467 | 99 |
31 Mar 15 | 1,508 | 182 | 457 | 100 |
31 Dec 14 | 1,486 | 182 | 448 | 98 |
30 Sep 14 | 1,488 | 199 | 435 | 96 |
30 Jun 14 | 1,443 | 193 | 422 | 93 |
31 Mar 14 | 1,405 | 190 | 409 | 89 |
31 Dec 13 | 1,377 | 188 | 401 | 88 |
30 Sep 13 | 1,343 | 188 | 381 | 87 |
30 Jun 13 | 1,320 | 185 | 370 | 85 |
Qualität der Erträge: IDXX hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: IDXXDie aktuellen Gewinnspannen (23.3%) sind höher als im letzten Jahr (20.4%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: IDXXIn den letzten 5 Jahren sind die Gewinne von 14.9% jährlich gestiegen.
Beschleunigtes Wachstum: IDXXDas Gewinnwachstum des Unternehmens im letzten Jahr (23.9%) übertrifft seinen 5-Jahres-Durchschnitt (14.9% pro Jahr).
Erträge im Vergleich zur Industrie: IDXX Das Gewinnwachstum im vergangenen Jahr (23.9%) übertraf das der Branche Medical Equipment 2.4% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: IDXXDie Eigenkapitalrendite des Unternehmens (55.2%) wird als hervorragend angesehen.